Medicalg (MDG) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Medicalg PLN 4.05, price PLN 25.20, upside -83.9%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medicalg for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range 5.75 PLN – 45.00 PLN · fair‑value band 3.60 PLN – 4.54 PLN · the 25.20 PLN price screens above the 4.05 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Follow Medicalg in your weekly email
Every Wednesday you see whether Medicalg is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medicalgorithmics S.A. provides cardiac diagnostic solutions in Poland, the United States, and internationally.
Show more
Medicalgorithmics S.A. provides cardiac diagnostic solutions in Poland, the United States, and internationally. It offers PocketECG, an AI-driven online ECG monitoring device for long-term holter, cardiac event, and mobile cardiac telemetry analysis; Kardiobeat.ai, an AI-Driven lightweight wireless holter monitor; DeepRhythm Platform, a hardware-agnostic cloud-based software that leverages cutting-edge AI technology to detect, classify, analyze, and report ECG data; and DeepRhythmAI, a set of algorithms for heart rhythm analysis that integrates into third-party software and devices. The company also provides virtual cardiac stress test (VCAST), an AI-based medical system developed for non-invasive, clinical quantitative, and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. In addition, it operates ECG TechBot, a software using a set of algorithms for automatic analysis and interpretation of the ECG signal based on deep learning methods. In addition, the company engages in the provision of information technology and ECG monitoring services; research and development, including the development of artificial intelligence (AI) algorithms and software for arrhythmia diagnostics, as well as the development and commercialization of AI-based VCAST cardiac imaging technology; and production of electromedical equipment. Medicalgorithmics S.A. company was incorporated in 2005 and is headquartered in Warsaw, Poland.
Stock analysis
Medicalg (MDG) currently trades at 25.20 PLN, while our model-based Fair Value estimate is 4.05 PLN, 83.9% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 3.60 PLN (bear) to 4.54 PLN (bull), the price of 25.20 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Medicalg reported revenue of 31.0M PLN in FY2025 versus 48.3M PLN in FY2021, a compound −10.5%/yr. Reported net income was −11.7M PLN in FY2025.
Key figures
Market cap 272M PLN (≈ $69.8M) · P/S ratio 7.89 · EPS (TTM) −0.9700 PLN · Net margin −37.7% · Return on equity −14.2% · Return on assets (EBIT) −2.2% · Operating margin −3.7% · Revenue (TTM) 34.4M PLN.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −84%, MDG screens richer than that median.
Fair Value models
Bear 3.60 PLNFair Value 4.05 PLNBull 4.54 PLN
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+29.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.6%
Start year 2020 (pandemic). Over 10 years: −4.5% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.6% (2020) → −26.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside−83.9% · Bottom 25%
Profitability
Return on assets−3.5% · Below median
Net margin (TTM)−28.0% · Bottom 25%
Operating margin (TTM)−3.7% · Below median
Growth and dividend
Revenue growth51.2% · Top 25%
Balance sheet
Debt / equity0.27× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.08× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)2.03× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 9
FUTURE (revenue growth)100· sector 31
PAST (return on equity)0· sector 11
HEALTH (low debt)87· sector 97
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medicalg Fair Value". https://www.fairvalue-calculator.com/stock/MDG
Frequently asked questions
Is Medicalg (MDG) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 4.05 PLN versus a price of 25.20 PLN, about −84% upside (overvalued).
What is the fair value of MDG?
Our model-based fair value for Medicalg is 4.05 PLN (as of Sep 13, 2026), built from audited fundamentals. The current price: 25.20 PLN.
What is the quality score of MDG?
Medicalg has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicalg (MDG)?
Our model-based price target is the fair value of 4.05 PLN (as of Sep 13, 2026) from 1 valuation models. Cautious scenario 3.60 PLN, optimistic scenario 4.54 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Medicalg stock forecast for 2026?
Our models put fair value at 4.05 PLN, about −84% upside versus a price of 25.20 PLN (overvalued). Cautious scenario 3.60 PLN, optimistic scenario 4.54 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Medicalg (MDG)?
Medicalg reported trailing-twelve-month revenue of about 34.4M PLN (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Medicalg (MDG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicalg it is 4.05 PLN per share (as of Sep 13, 2026), against a price of 25.20 PLN. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Medicalg stock overvalued or undervalued in 2026?
As of Sep 13, 2026, MDG trades above its calculated fair value: price 25.20 PLN, fair value 4.05 PLN, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDG?
No. The price is what the market pays today (25.20 PLN); the fair value is what the company's own numbers justify (4.05 PLN). For Medicalg the two are 21.15 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicalg worth?
The market values Medicalg at about 272M PLN (market capitalisation, as of Sep 13, 2026). Per share that is 25.20 PLN; our models calculate a fair value of 4.05 PLN per share.
What do the bullish and bearish scenarios say about MDG?
Our models span a range for Medicalg: cautious scenario 3.60 PLN, base 4.05 PLN, optimistic 4.54 PLN per share (as of Sep 13, 2026, price 25.20 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medicalg (MDG)?
Balance-sheet figures for Medicalg (as of Sep 13, 2026): return on equity −14.2%, debt of 0.27 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is MDG from its 52-week high?
Medicalg trades at 25.20 PLN, about 36% below its 52-week high of 39.25 PLN and 3% above the low of 24.50 PLN (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 4.05 PLN is for.
Which stocks are comparable to Medicalg?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicalg stock attractive at the current price?
The data as of Sep 13, 2026: price 25.20 PLN, calculated fair value 4.05 PLN (−84%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDG calculated?
We run Medicalg through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.05 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medicalg itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicalg (MDG)?
The closing price on Oct 2, 2026 was 25.20 PLN. Our model-based fair value is 4.05 PLN, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicalg right now?
The price sits above even our optimistic bull case (4.54 PLN). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Medicalg
How large is the market capitalisation of Medicalg (MDG)?
The market capitalisation of Medicalg is 272M PLN (≈ $69.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicalg (MDG)?
The price-to-sales ratio of Medicalg is 7.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medicalg (MDG)?
Earnings per share at Medicalg are −0.9700 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medicalg (MDG)?
The net margin of Medicalg is −37.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medicalg (MDG)?
The return on equity (ROE) of Medicalg is −14.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicalg (MDG)?
On an EBIT basis the return on assets of Medicalg is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicalg (MDG)?
The operating margin of Medicalg is −3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicalg (MDG)?
Revenue at Medicalg is growing +51.2% versus a year earlier (3y avg −20.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medicalg (MDG) generate?
The free cash flow of Medicalg is −15.6M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medicalg (MDG) carry?
The net debt of Medicalg is 16.2M PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medicalg in the live analysis
One click puts Medicalg on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
